SloveniaSlovenia

EIB loan: BIA Separations expands

29.04.2009

Ljubljana – BIA Separations d.o.o., the Slovenian specialist for downstream processing of biologicals using monoliths, has received an EUR8m cash injection from the European Investment Bank (EIB). EIB president Philippe Maystadt and Dr. Aleš Štrancar, the company’s CEO, signed the loan agreement, making BIA the first European SME to receive a loan under the Risk Sharing Finance Facility (RSFF) scheme, a joint venture between the European Commission and EIB intended to improve access to debt financing for private companies. “We will put the money into the development of our new purification technologies for the biopharmaceutical industries and expand into a new 3000 m2 R&D and production facility,” BIA’s international marketing manager Gregor Krajnc told EuroBiotechNews. BIA’s methacrylate polymers can be used in short chromatographic resins and offer an improved separation capa­city for large biological molecules such as pegylated proteins and antibodies compared to conventional chromatographic media. While production capacities for biologicals has expanded partly up to the 10g/l range, downstream processing has increasingly become a bottleneck in production processes. Conventional sepa­ration techniques suffer from limited mass transfer.

New biotech center

Additionally, the company laid the cornerstone for a new facility located in Ajdovšcina. With this expansion of its production capacity 50 kilometres west of the Slovenian capital Ljubljana, BIA Separations is moving into a high-technology oriented region where it will, in conjunction with University of Nova Gorica, establish a biotech incubator for the region. One of the roles the incubator will play is to help in the establisment of a biotechnology programme at the nearby university, thereby creating a pool of highly educated personnel for BIA Separations and other companies moving into the region, and meeting long-term human resources.

SloveniaSlovenia

05.03.2010

Ljubljana – Slovenian drugmaker Krka d.d. turned in a solid performance in 2009, with total sales reaching EUR950m, similar to turnover in 2008. Profits rose by around 10% year-on-year to EUR173.7m. The results announced at the...

SloveniaSlovenia

27.08.2009

Ljubljana – Pharma giants Warner-Lambert and Pfizer have withdrawn their lawsuit against the Slovenian generic manufacturer Krka d.d over the infringement of two patents concerning their US$12bn blockbuster drug Lipitor...

SloveniaSlovenia

21.02.2009

Ljubljana – The most talented young synthetic biologists currently seem to be coming from Eastern Europe. After its success in 2006, a team of young undergraduate chemists from the University of Ljubljana has once again won the...

SloveniaSlovenia

01.11.2008

Belgrade/Lund – Swedish developer of probiotic bacteria Probi AB (Lund) has signed a distribution agreement with Serbian pharmaceutical company Proton System (Belgrade). The agreement gives Proton System the right to sell one of...

SloveniaSlovenia

14.02.2008

Ljubljana/Brussels – Slovenia, which took over the EU presidency from Portugal in January, will put its health-care focus on improving the management of cancer, representatives announced on the presidency website...

Germany, SloveniaSlovenia

24.10.2007

Zagreb – Barr-PLIVA d.d.’s German subsidiary AWD.pharma GmbH & Co. KG. has signed an agreement to acquire O.R.C.A.pharm GmbH (“ORCApharm“), a privately owned specialty pharmaceutical company focused on the oncology market in...

SloveniaSlovenia

17.05.2007

Ljubljana – Slovenia’s national prevention scheme has led to a very low rate of new HIV infections. According to Slovenias’ health minister, Andrej Brucan, fewer than one in 1000 people is infected with the AIDS virus.

SloveniaSlovenia

21.11.2006

Zagreb – Consolidation of the generic-drug business is focusing on eastern Europe. So far in 2006, at least eight deals have been announced, including Barr Pharmaceuticals‘ US$2.5-billion acquisition of Croatia‘s Pliva, completed...

SloveniaSlovenia

21.07.2006

Zagreb – In the bidding race between the Icelandic Actavis Group and US Barr Pharmaceuticals Inc. for the takeover of the Croatian biogenerics producer Pliva d.d., the company ultimately opted for Barr’s offer. Both companies’...

SloveniaSlovenia

17.03.2006

Ljubljana - Lek, the wholly-owned Slovenian subsidiary of Sandoz, Novartis' generics business, will once again cut up to 50 jobs through the course of the year. The redundancies are expected to hit all departments except R&D and...

Displaying results 1 to 10 out of 22

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-slovenia/article/eib-loan-bia-separations-expands.html

Product of the week

Products

Events

All Events

Current issue

All issues